The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How should we monitor patients on novel agents such as venetoclax?

During the 3rd Annual Meeting of the International Academy for Clinical Hematology (IACH), the AML Hub was pleased to speak to Thomas Prebet, Yale School of Medicine, New Haven, US. We asked: How should we monitor patients on novel agents such as venetoclax?

How should we monitor patients on novel agents such as venetoclax?

Thomas Prebet discusses key considerations when monitoring patients treated with the combination of hypomethylating agents and venetoclax. He focuses on two main areas: Safety monitoring within the first weeks of treatment, mainly for tumor lysis syndrome, myelosuppression, and cytopenia; Efficacy monitoring by regular assessment of response to treatment.

Share: